FDA stops trials of Amgen's Sensipar after teen's death

02/27/2013 | Reuters

The FDA halted all clinical trials of Amgen's Sensipar involving children following the death of a 14-year old. The agency said it is not sure whether Sensipar, which is approved for the reduction of blood calcium levels in adults, had a role in the death. "Amgen is working as rapidly as possible to understand the circumstances of what happened. This analysis is ongoing and will be concluded as quickly as possible," the firm said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI